全国累计接种新冠病毒疫苗超过1亿剂次

3月28日举行的国务院联防联控机制新闻发布会正式宣布，

 

China had administered more than 100 million doses of COVID-19 vaccines¹ by Saturday.

截至3月27日24时，全国累计报告接种新冠病毒疫苗超过1亿剂次。

 

国家卫健委疾控局副局长吴良有在发布会上表示，

 

Beijing and Shanghai have started vaccinating³ people over 60 who are in good health and those who have chronic⁴ disease.

北京、上海等地已经陆续开展了针对60岁以上身体健康状况良好的老年人群的疫苗接种。

 

The country will actively⁵ and prudently⁶ advance the COVID-19 vaccination⁷ of people over 60 and those who have chronic disease, based on the effectiveness of its mass vaccination campaign.

下一步将结合疫苗在大规模人群中的使用效果，积极稳妥推进60岁以上人群和慢性病患者的疫苗接种工作。

 

未来疫苗接种还将覆盖18岁以下人群

 

国药集团中国生物副总裁张云涛表示，

 

China National Biotech Group will start consultations⁸ with the National Medical Products Administration on the vaccination of those aged⁹ between 3 and 17, and it is expected to start soon.

对于3-17岁人群的接种工作，中国生物近期将和药监局作沟通。

 

The company started early and mid-stage clinical trials of vaccinations¹⁰ for people in that age group in Henan province last year, Zhang said.

去年中国生物在河南现场开展的I/II期临床研究的过程中就涵盖了3-17岁年龄段的临床研究。

 

The trials have shown that the vaccine²'s safety met expectations, and data on its effectiveness has also been obtained, he said.

目前这个年龄段的安全性数据已获得，达到了预期效果，有效性数据也已获得。

 

两款灭活疫苗对不同地区的10多株毒株有中和作用

 

近期国外频频发现变异新冠病毒，引发许多人对于我国疫苗有效性的担忧。对此，张云涛介绍，

Researchers have been testing the antiviral-mutation ability of the inactivated¹¹ vaccines.

研究人员对灭活疫苗对抗变异病毒的能力进行了实验。

 

By using data from mid-and late-stage clinical trials in China and overseas, researchers have conducted experiments on a dozen variants¹², including those found in South Africa and the United Kingdom, Zhang said.

研究人员利用在国内和海外二期、三期临床试验后的血清，对包括南非发现的、英国发现的毒株，还有国内不同地区、不同流行区发现的10多株的毒株进行了交叉综合实验。

 

The experiments have found that the antibodies produced by the two inactivated vaccines have a good neutralizing¹³ effect on all the tested strains, he said, adding that such experiments are continuing on strains found in Brazil and Zimbabwe.

结果显示，两款灭活疫苗产生的中和抗体对这些毒株都有很好的中和作用。目前，国药集团中国生物在对巴西、津巴布韦发现的毒株进行中和实验监测。

 

北京科兴中维生物技术公司总经理高强也表示，

The company has started research and development of vaccines against the variants discovered in South Africa and Brazil.

科兴中维同时已经启动了对南非株、巴西株的疫苗研发工作。

 

Based on earlier cross-neutralization research on mutated strains found in 10 countries, its vaccine has proved to be effective, he said.

在研究初期已经对10个国家病毒株的变异进行中和试验，已经证明了当时研发的疫苗对各个国家的变异株是有保护作用的。

分享到：